Predictive Oncology’s Skyline Medical Division Expands Its Asian Market Share with First-Ever Orders of STREAMWAY Systems i...
August 06 2019 - 8:00AM
Predictive Oncology, Inc. (Nasdaq: POAI) (“Predictive Oncology” or
“the Company”), today announced its Skyline Medical division has
received its first order from India for four machines to be sold to
local hospitals.
“The sale of these four STREAMWAY units in India marks our entry
into that country, and is an exciting milestone in our continued
market expansion,” commented Dr. Carl Schwartz, chief executive
officer of Predictive Oncology.
The Indian healthcare industry is estimated to be more than $100
billion with the nation’s medical device industry valued at more
than $6 billion.1
To be added to the Predictive Oncology database, please email
Info@MoneyInfo-llc.com with your email address. This is solely for
the use of Predictive Oncology and will not be sold or distributed
to third parties.
About the STREAMWAY SystemSkyline's
revolutionary, FDA-cleared STREAMWAY System is the
first true direct-to-drain fluid disposal system designed
specifically for medical applications, such as radiology,
endoscopy, urology and cystoscopy procedures. It connects directly
to a facility's plumbing system to automate the collection,
measurement and disposal of waste fluids.
The STREAMWAY minimizes human intervention for better safety and
improves compliance with Occupational Safety and Health
Administration (OSHA) and other regulatory agency safety
guidelines. It also provides unlimited capacity for increased
efficiency in the operating room, which leads to greater
profitability. Furthermore, the STREAMWAY eliminates canisters to
reduce overhead costs and provides greater environmental
stewardship by helping to eliminate the approximately 50 million
potentially disease-infected canisters that go into landfills
annually in the U.S. For a demonstration please
visit www.skylinemedical.com or call 855-785-8855.
About Predictive Oncology Inc.Predictive
Oncology (formerly Precision Therapeutics Inc.) (Nasdaq: POAI)
operates through its three business units, Helomics, TumorGenesis
and Skyline Medical. Helomics applies artificial intelligence to
its rich data gathered from patient tumors to both personalize
cancer therapies for patients and drive the development of new
targeted therapies in collaborations with pharmaceutical companies.
Helomics’ CLIA-certified lab provides clinical testing that assists
oncologists in individualizing patient treatment decisions, by
providing an evidence-based roadmap for therapy. In addition to its
proprietary precision oncology platform, Helomics offers boutique
CRO services that leverage its TruTumor™, patient-derived tumor
models coupled to a wide range of multi-omics assays (genomics,
proteomics and biochemical), and an AI-powered proprietary
bioinformatics platform (D-CHIP) to provide a tailored solution to
its clients’ specific needs. Predictive Oncology’s TumorGenesis
subsidiary is developing a new rapid approach to growing tumors in
the laboratory, which essentially “fools” cancer cells into
thinking they are still growing inside a patient. Its proprietary
Oncology Discovery Technology Platform kits will assist researchers
and clinicians to identify which cancer cells bind to specific
biomarkers. Once the biomarkers are identified they can be used in
TumorGenesis’ Oncology Capture Technology Platforms which isolate
and help categorize an individual patient’s heterogeneous tumor
samples to enable the development of patient specific treatment
options. Helomics and TumorGenesis are focused on ovarian cancer.
Predictive Oncology’s Skyline Medical division markets its patented
and FDA cleared STREAMWAY System, which automates the collection,
measurement and disposal of waste fluid, including blood,
irrigation fluid and others, within a medical facility, through
both domestic and international divisions. The company has achieved
sales in five of the seven continents through both direct sales and
distributor partners. For more information, please visit
www.predictiveoncology.net.
Forward-looking Statements Certain of the
matters discussed in the press release contain forward-looking
statements that involve material risks to and uncertainties in the
Company’s business that may cause actual results to differ
materially from those anticipated by the statements made herein.
Such risks and uncertainties include (i) risks related to the
recent merger with Helomics, including the fact that the combined
company will not be able to continue operating without additional
financing; possible failure to realize anticipated benefits of the
merger; costs associated with the merger may be higher than
expected; the merger may result in disruption of the Company’s and
Helomics’ existing businesses, distraction of management and
diversion of resources; and the market price of the Company’s
common stock may decline as a result of the merger; (ii) risks
related to our partnerships with other companies, including the
need to negotiate the definitive agreements; possible failure to
realize anticipated benefits of these partnerships; and costs of
providing funding to our partner companies, which may never be
repaid or provide anticipated returns; and (iii) other risks and
uncertainties relating to the Company that include, among other
things, current negative operating cash flows and a need for
additional funding to finance our operating plan; the terms of any
further financing, which may be highly dilutive and may include
onerous terms; unexpected costs and operating deficits, and lower
than expected sales and revenues; sales cycles that can be longer
than expected, resulting in delays in projected sales or failure to
make such sales; uncertain willingness and ability of customers to
adopt new technologies and other factors that may affect further
market acceptance, if our product is not accepted by our potential
customers, it is unlikely that we will ever become profitable;
adverse economic conditions; adverse results of any legal
proceedings; the volatility of our operating results and financial
condition; inability to attract or retain qualified senior
management personnel, including sales and marketing personnel; our
ability to establish and maintain the proprietary nature of our
technology through the patent process, as well as our ability to
possibly license from others patents and patent applications
necessary to develop products; Predictive Oncology’s ability to
implement its long range business plan for various applications of
its technology; Predictive Oncology’s ability to enter into
agreements with any necessary marketing and/or distribution
partners and with any strategic or joint venture partners; the
impact of competition, the obtaining and maintenance of any
necessary regulatory clearances applicable to applications of
Predictive Oncology’s technology; and management of growth and
other risks and uncertainties that may be detailed from time to
time in the Company’s reports filed with the SEC, which are
available for review at www.sec.gov. This is not a solicitation to
buy or sell securities and does not purport to be an analysis of
Predictive Oncology’s financial position. See Predictive Oncology’s
most recent Annual Report on Form 10-K, and subsequent reports and
other filings at www.sec.gov.
Contacts: Investor Relations CORE IR Bret
Shapiro (212) 896-1203 brets@coreir.com
Media Jules Abraham CORE IR julesa@coreir.com
917-885-7378
_________________________________1
https://www.advamed.org/sites/default/files/resource/medical_industry_in_india_-_the_evolving_landscape_oppurtunities_and_challenges_white_paper.pdf
Predictive Oncology (NASDAQ:POAI)
Historical Stock Chart
From Mar 2024 to Apr 2024
Predictive Oncology (NASDAQ:POAI)
Historical Stock Chart
From Apr 2023 to Apr 2024